Vertex Pharmaceuticals price target raised to $450 from $400 at Piper Sandler

Piper Sandler raised the firm’s price target on Vertex Pharmaceuticals to $450 from $400 and keeps an Overweight rating on the shares. The firm continues to like the setup for Vertex, with continued upside for the cystic fibrosis franchise anticipated in addition to an industry-leading pipeline, the analyst tells investors in a research note.